HAIFA, Isreal, December 2 /PRNewswire-FirstCall/ -- Cardio Vascular Medical Device Corp. (CVSL.OB), a leading developer of advanced cardiovascular surgery technology, today announced that the company’s Board of Directors approved a one-for-three forward stock split, in the form of a stock dividend, payable to Cardio Vascular Medical Device shareholders.
The Company will announce in due course the estimated date the stock split will be payable and the related record date of the shareholders. The stock split is subject to FINRA approval. When the forward stock split becomes effective, shareholders of common stock will receive an additional two shares for each share held at the record date.
“We are pleased to announce this forward stock split for our shareholders,” stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp. “We expect that the Board’s decision will improve liquidity and trading volume in our company’s stock.”
About Cardio Vascular Medical Device
Cardio Vascular Medical Device holds a US patent for an innovative next-generation “steerable guidewire” applicable for all angioplasty (PCTA) procedures. The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.
Learn more about Cardio Vascular Medical Device at: http://www.cvslmedical.com
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Cardio Vascular Medical Device Corp. and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated in the forward-looking statements. Cardio Vascular Medical Device Corp. public filings may be viewed at http://www.sec.gov.
CONTACT: Contact: Alex Traiman, Media Relations, +1-646-863-9729; Asher
Zwebner, +972-54-464-6363, asher@fxmng.com
